Boehringer Ingelheim and Inventiva Partner to Develop New Treatments for Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim and Inventiva recently signed a new multi-year drug discovery and research partnership and licensing agreement. Research teams from both companies will jointly work to validate a new therapeutic concept with the purpose of finding novel therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. The…